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Introduction
Creatine phosphokinase (CPK), also known as
creatine kinase (CK), is an enzymatic protein,
belonging to the wide family of kinases (or phos-
photransferase), therefore able to transfer phosphate
groups from high-energy donor molecules (e.g.
adenosine triphosphate, ATP) to specific substrates
(phosphorylation). Tissues, where this enzyme is
most represented in, are the ones whose metabolism
involves rapid energy consumption, such as
myocardium, striated muscle, smooth muscle, reti-
na photoreceptor cells, brain, and sperm. CPK
serum concentration increase can be noticed in sev-
eral diseases, including rhabdomyolysis, myode-
generative diseases, such as Duchenne muscular
dystrophy, myocardial infarction, and acute renal
failure(1-3).
According with the different localization
(myocardium, striated muscle, and brain) and func-
tion, several CPK isoenzymes have been identified,
some cytosolic, other mitochondrial. As a matter of
fact, CPK is a dimer composed of two different
subunits. There are at least three cytosolic localiza-
tion of CK isoenzymes: CK-MM, CK-BB and CK-
MB. Genes involved in subunits synthesis are,
respectively, B and M, in 4q32 and 19q13 locus. In
Table 1 are listed genes, their respective locations,
and the expressed isoenzyme proteins(4-7).
Cytosolic CPK acts regenerating ATP from
ADP and phosphocreatine, contrariwise mitochon-
drial isoenzymes is directly involved in ATP mito-
chondrial synthesis from phosphocreatine. MM iso-
form is localized in the sarcomeres, presenting,
both in the myocardium and in the skeletal muscle,
MB isoform presents, instead, single myocardial
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expression, and BB isoform is, finally, expressed in
smooth muscle and in several other tissues.
Mitochondrial isoforms are ubiquitously
expressed(1,8).
CPK serum concentration is routinely required
in many clinical conditions, especially in patients
suffering from chest pain and acute renal failure.
Nevertheless, its increase, especially MM isoen-
zyme, is a sensitive and specific muscle damage
index, both traumatic and metabolic/inflammatory
(crush syndrome, rhabdomyolysis, alcohol and/or
drugs damage, and polymyositis)(1-8).
The following case report is representative of
asymptomatic hyper-CPKemia in an women, aged
65 years, secondary to recurrent syncopal episodes,
by altered cerebral blood flow, with consequential,
repeated, ground falls, initially undiagnosed, due to
patient lack of cooperation in history collection.
Case report
A 65 years old, non smoker, woman was
admitted to our Department, as outpatient, due to
the onset, for almost a month, of persistent legs
weakness and right shoulder pain. The patient did
not report anything significant, except for essential
hypertension, treated with angiotensin II receptor
blockers, since 2005.
Clinical examination showed no abnormali-
ties, except for pain during active and passive
movements of the right shoulder; similarly, routine
hematochemical blood tests (complete blood count,
liver and renal function test, glycaemia, natraemia,
kalaemia, calcaemia, magnesaemia, iron metabo-
lism, electrophoresis of proteins) were all in the
normal range.
Electrocardiogram showed left ventricular
overload nonspecific signs (ST segment depression
in inferior and lateral leads), and 24-hour ambulato-
ry blood pressure monitoring (“arterial hyperten-
sion well controlled by the therapy”) and
echocardiography (ejection fraction
60%, mild mitral regurgitation, with
mildly dilated left atrium) were per-
formed. Patient underwent a venous
lower limbs Doppler ultrasound, also
within the limits, except for left tibial
veins slight ectasia and incontinence,
with evidence of some perforating vein
that feeds small superficial veins of the
leg.
Patient was then revaluated ten days
after first admission, reporting persis-
tence of the above-mentioned symptoms.
Physical examination was unchanged, as
well as blood tests, except for a CPK
(245 IU/L, r.r. female 26-192 IU/L) and lactate
dehydrogenase (LDH) (527 IU/L, r.r. 240-480
IU/L) isolated increase.
Patient underwent carotid Doppler ultrasound
(“tortuosity of left vertebral artery, V2 segment”),
thyroid ultrasound (“bilateral subcentimeter
hypo/anechoic nodules”), upper and lower
abdomen ultrasound (“presence of three cysts in the
liver, one in S2 and S3 of 0.8 cm maximum diame-
ter, the others, subcapsular, in correspondence of
S4, the maximum diameter of, respectively, 0.7 and
0.3 cm), and ultrasonography of right shoulder joint
(“nonspecific right shoulder periarthritis”).
Subsequent outpatient visit demonstrated per-
sistence of elevated CPK and LDH values, without
any change in physical findings and chemistry para-
meters. Dual-emission X-ray absorptiometry, point-
ing out a “senile osteoporosis framework” (lumbar
T-score: -2.6 SD; left femoral T-score: -1.9 SD),
and a whole spine x-ray, showing “radiological
signs of cervical, dorsal and lumbar spondylarthro-
sis, D11, D12 and L1 vertebral bodies minor wedge
fracture, interbody space shrinkage from C4 to C7
and L5-S1”, were also performed.
Due to the persisting rise of CPK and LDH,
thyroid and parathyroid hormones (all within nor-
mal limits), and non organ-specific autoantibodies
(anti-dsDNA, ANA, anti-Jo-I, anti-nRNP, anti-Scl-
70, anti-Sm, anti-Ro, anti-La and anti-ENA, all
negative) assays were performed, as well as aden-
oviruses, coxsackievirus, herpes viruses, human
immunodeficiency virus, Salmonella, Brucella,
Gene Locus Protein Isoenzyme Tissue location
CKB Chr. 14 q32.3 Creatine phosphokinase BB, MB Brain
CKBE Chr. 14 q32.3 Creatine phosphokinase None Ectopic expression









CKMT2 Chr. 5 q13.3 Mitochondrial creatinephosphokinase 2
mtCK, or
smtCK Sarcomeric
Table 1: CPK genes and isoenzymes expression.
Legionella and Listeria serology and celiac disease
antibodies test (anti-gliadin, anti-tissue transglutam-
inase, anti-endomysial), all resulting within refer-
ence range.
During a subsequent control, considering the
persistence of CPK and LDK increase, medical his-
tory was revaluated, paying particular attention to
pharmacological history, without encountering
intake of drugs and/or food able to determine isolat-
ed CPK increase. A new physical examination was
performed, highlighting upper and lower limbs
bruises; appropriately questioned, patient reported
something that she wilfully neglected, cause it
‘seemed unimportant’. She referred that, for about 3
months, had suffered from repeated lipothymia
episodes, which led to several ground falls, during
daily routine duties, which only recently begun to
emerge as superficial hematoma. For this reason,
24h ambulatory ECG monitoring (within limits),
carotid Doppler ultrasound re-evaluation (“left ver-
tebral artery flow rate reduction”, and brain CT
scan with intravenous contrast (“chronic cere-
brovascular disease framework”) were performed.
The patient was dismissed with final diagnosis of
'syncopal-like episodes, with multiple ground falls
and increasing of CPK serum levels, in patients
affected with left vertebrobasilar insufficiency,
essential hypertension, senile osteoporosis, compli-
cated by vertebral fractures (D11-D12-L1), right
shoulder not specific periarthritis, mild to moderate
peripheral venous insufficiency, and non-toxic
multinodular goitre’. Therefore, patients started
treatment with ASA (300mg/die), strontium
ranelate (2g/die) and cholecalciferol (2,500IU/die).
The patient was then readmitted to our outpa-
tient, to perform clinical and hematochemical fol-
low-up, at three, six and twelve months, with syn-
copal episodes disappearance and progressive and
complete CPK and LDH values normalization.
Discussion
CPK is an essential enzyme in cell energy
metabolism, since it has the property of forming
ATP, starting from creatine phosphate and ADP.
Reaction reversibility allows rapid production, use
and release of energy. CPK may be found in high
amounts in myocardium, skeletal muscle, retina
photosensitive cells, brain and sperm, in minor
amounts, in smooth muscle, thyroid, kidney and
liver. Three different isoenzymes, diagnostically
significant, have been proved: CPK-MM, or mus-
cular type, which represents about 95% of total
CPK, CPK-MB, or heart type, which represents
about 5%, and CPK-BB, or brain type, which usual-
ly is never found in healthy subjects, as blood-brain
barrier prevents its passage into general blood cir-
culation. These isoenzymes are exclusively cyto-
plasmic, although, more recently, has been identi-
fied mitochondrial isoforms, placed on the inner
surface of the mitochondrial outer membrane(1).
Due to the variability of normal ranges estab-
lished by different assessment methods, CPK
increase may be defined, in relation to the maxi-
mum normal value, as: “mild” (equal or less than to
2 times normal value), “moderate” (greater than
two and less than 4 times normal value), “marked”
(greater than 4 and less than 10 times normal
value), “severe” (greater than 10 times normal
value). Usually, values in women are about half
those observed in men(9). Infants physiologically
present total CPK high value up to 10 times normal,
probably due to physiological stress of childbirth,
which generally falls within the limits already at
day 4, but sometimes may remain elevated for up to
6-10 weeks(10).
CPK increase can occur under 'paraphysiologi-
cal' conditions such as: increase in outside tempera-
ture, with values greater than 37° C; subjects com-
ing from equatorial countries or at least most
exposed to sunlight; physical exercise, even in
trained people or athletes; intense or unusual sport-
ing activity(11-15). 
Causes of pathological CPK serum increase
are listed in Table 2(16,17).
In neuromuscular diseases, CPK value can rise
up to 50 to 100 times normal range, as seen in sev-
eral kind of muscular dystrophy, the most serious
and widespread of which is surely Duchenne pro-
gressive muscular dystrophy, associated with typi-
cal muscle symptoms, which could guide to diagno-
sis(18-20). Acute myocardial infarction is associated
with CPK-MB early increase, whose serum patho-
logical values can be found just after 4-6 hours
from chest pain onset, its peaks just between 16 and
20 hours, and its fall, usually, within 48 hours,
unless there is infarction area expansion(21-23).
Particular attention should be given to drugs
assumption: statins treatments in patients with high
cholesterol levels can lead to mild to moderate lev-
els serum CPK increase, sometimes associated with
mild muscle symptoms, which usually regress after
drugs discontinuation(24-26). Other drugs that can pro-
duce an increase in serum CPK are anticoagulants,
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morphine, alcohol, high doses of salicylates,
amphotericin B, fibrates, antiretroviral drugs,
beta-blockers, immunosuppressive drugs,
hydroxychloroquine and some general anesthet-
ics (individuals who have a predisposition to
malignant hyperthermia may present hyper-
CPKemia before surgery, in absence of other
clinical symptoms, which must induce physicians
to use safe anesthetic protocol)(27-35).
Finally, in literature, it is reported a condition,
known as ‘Idiopathic benign hyper-CPK-emia’, in
which it can be observed a persistent elevation of
CPK in an asymptomatic patient, with normal neu-
rological and laboratory findings. It can be a familial
condition in up to 46% of the cases. Familial IH is a
benign genetically heterogeneous condition that is
autosomal-dominant in at least 60% of cases, with a
higher penetrance in men(17,36,37).
Our patient showed recent onset of mild-to-
moderate hyper-CPKemia, associated with
increased serum LDH, in absence of associated
muscle or cardiac symptoms/signs, so, after
exclusion of neuromuscular disease family histo-
ry and presence of acute or chronic muscle/heart
damage, we accounted all others possible sec-
ondary hyper-CPKemia causes. Patient denied
she had undergone, in the recent past, to unusual
physical exertion, or to have been engaged in
sports activity, or have suffered from muscular
trauma of any kind. Medical history was silent
for fever, muscle tremors, seizures, dystonia,
intramuscular injections, surgery or other inva-
sive procedures. Drug history was negative about
assumption of statins and/or other drugs able to
cause muscle damage. Normality of all the other
blood tests allowed also to exclude kidney and
liver failure or electrolyte imbalances, as well as
the negativity of serological infective, autoim-
mune, endocrine and inflammatory markers per-
mitted the exclusion of infections, connective tis-
sue diseases and endocrine disorders.
Finally, after a more careful and mastered clin-
ical history interview, patient reported the late
onset of syncopal episode during the course of
normal daily tasks, moreover associated with
physician’s detection of lower limbs hematoma.
These data, combined with the report of carotid
Doppler ultrasound and brain CT scan with intra-
venous contrast, induced us to make final diagno-
sis of hyper-CPKemia; secondary to recurrent
syncopal episodes, with repeated ground falls, in
patients with impaired cerebral blood flow.







• high fever with chills
• seizures or severe dystonia
• diagnostic procedures (electromyography) 
• intramuscular therapies: 
by needle direct action on striated muscles





• muscular dystrophies (Duchenne progressive muscular dystrophy, etc..) 
• spinal amyotrophy (amyotrophic lateral sclerosis, etc.)
Metabolic myopathies
• glycogenolysis abnormalities (myophosphorylase kinase deficiency, phosphorylase
kinase deficiency)
• glycolysis abnormalities (phosphofructokinase deficiency, phosphoglycerate kinase
deficiency, phosphoglycerate mutase deficiency, lactate dehydrogenase deficiency)
• lipid metabolism abnormalities (carnitine deficiency, carnitine palmitoyltransferase II
deficiency, short-chain acyl-CoA dehydrogenase deficiency, very long chain acyl-CoA
dehydrogenase deficiency)
• purine metabolism abnormalities (monoadenenylate deaminase deficiency)














Other disease (infections, organ and endocrine diseases):
• viral infections (influenza and parainfluenza virus, adenovirus, coxsackievirus,
echovirus, herpes virus)
• bacterial infection (streptococcus, staphylococcus, salmonella, legionella, listeria,)
• cardiologic disease (acute myocardial infarction, myocarditis, etc. [CPK-MB isoen-
zyme increase]
• kidney disease (acute renal failure, chronic renal failure)
• connective tissue disease (polymyositis, dermatomyositis, systemic lupus erythema-
tous)
• celiac disease
• endocrine disorders (hypothyroidism, thyrotoxicosis, hypoparathyroidism, hyper-
parathyroidism, diabetic ketoacidosis, non ketoacidosic hyperosmolar diabetic coma)
• acute electrolyte disturbances (hyponatraemia, hypernatraemia, hypokalaemia, hyper-
kalaemia, hypocalcaemia, hypercalcaemia, hypomagnesaemia, hypermagnesaemia)
Idiopathic benign hyper-CPK-emia
Table 2: CPK increase aetiology.
Conclusions
Serum CPK increased levels may be epiphe-
nomenon of several diseases, which produce, either
directly or indirectly, myocardium or
skeletal/smooth muscle damage. Accounting type
and abundance of possible etiologic agents to be
investigated, and consequently the amount of blood
chemistry and instrumental tests, a through medical
history can help to solve this clinical question.
Among all possible causes, direct muscle trauma is
undoubtedly the most frequent, especially in the
elderly population. The clinical case we reported
shows that multiple syncopal episodes, and conse-
quent falls to the ground, may be the correct and
‘trivial’ explanation of a pathological increase in
CPK serum levels. For this, an accurate patient his-
tory investigation, 'urging' also those information
that may be silenced by the patient, as well as
carotid Doppler ultrasound and possibly, if
risk/benefit ratio would make it appropriate, brain
CT scan, should be included in CPK pathologic
increase diagnostic work-up.
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